Bank of America Securities Maintains a Neutral Stance on Pfizer Inc. (PFE)

Pfizer Inc. (NYSE:PFE) is one of the best large cap value stocks to buy now. On September 23, Bank of America Securities analyst Tim Anderson maintained a neutral stance on Pfizer Inc. (NYSE:PFE), giving the stock a Hold rating with a $28 price target.

The analyst supported the rating with the company’s financial outlook and strategic moves, stating that Pfizer Inc.’s (NYSE:PFE) acquisition of Metsera is a notable and positive step in entering the obesity market.

However, Anderson added that the acquisition’s full potential is contingent on several pipeline-related milestones, and the deal is still subject to shareholder approval and other conditions.

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures in developing and emerging markets.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.